Table 1.
Clinical and demographic characteristics of 379 male patients with genital Human Papillomavirus (HPV) infection who received quadrivalent HPV vaccination, at study initiation (T0). Data were stratified according to vaccine responding at 6 months after the end of the vaccination cycle (12 months since study initiation, T1). Abbreviations: Resp. = Responding; Non-Resp. = Non-Responding; SEM = Standard error of the mean; BMI = Body mass index. Significant p-Values are in bold.
| Comparison of Data at T0 (Study Initiation) | ||||
|---|---|---|---|---|
| Parameters | Whole Population N = 379 |
Resp. at T1 326/379 (86%) |
Non-Resp. at T1 53/379 (14%) |
p-Value (Resp. vs. Non-Resp.) |
| Mean age (years ± SEM) | 40.3 ± 0.65 | 39.8 ± 0.48 | 41.5 ± 1.44 | 0.9999 |
| BMI (kg/m2 ± SEM) | 23.9 ± 0.2 | 24.1 ± 0.19 | 23.6 ± 0.41 | 0.3175 |
| Concomitant drug therapy (n/%) | 104/379 (27.4%) | 82/326 (25%) | 22/53 (41.5%) | 0.0194 |
| Genital Warts (n/%) | 123/379 (32.4 %) | 90/326 (27.6%) | 33/53 (62.3%) | 0.0001 |
| HPV Genotypes | ||||
| Vaccine genotypes (n/%) | 227/379 (59.9 %) | 191/326 (58.6%) | 36/53 (67.9%) | 0.2281 |
| Cross-reactive genotypes (n/%) | 152/379 (40.1%) | 135/326 (41.4%) | 17/53 (32.1%) | 0.2281 |